baicalin has been researched along with favipiravir in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aquino, TM; Araújo-Júnior, JX; da Silva-Júnior, EF; Leoncini, GO; Rodrigues, ÉES | 1 |
| Beccari, AR; Cannalire, R; Cerchia, C; Di Leva, FS; Summa, V | 1 |
2 review(s) available for baicalin and favipiravir
| Article | Year |
|---|---|
The medicinal chemistry of Chikungunya virus.
Topics: Animals; Antiviral Agents; Biological Products; Chemistry, Pharmaceutical; Chikungunya Fever; Chikungunya virus; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship | 2017 |
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
Topics: Antiviral Agents; Coronavirus 3C Proteases; COVID-19; COVID-19 Drug Treatment; Humans; Molecular Structure; Protease Inhibitors; RNA-Dependent RNA Polymerase; SARS-CoV-2 | 2022 |